Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
October 15, 2021 at 08:30 am EDT
Share
Vir Biotechnology, Inc. announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American ssociation for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place virtually from November 12-15, 2021. Among the accepted abstracts is an oral presentation of new data from a Phase 2 study evaluating VIR-2218, an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi), alone and in combination with pegylated interferon alfa-2a (PEG-IFNa), an approved immunomodulator for the treatment of chronic hepatitis B virus (HBV), for the potential functional cure of chronic HBV infection. Additionally, two poster presentations will highlight pre-clinical and clinical data for VIR-3434, an investigational HBV-neutralizing monoclonal antibody designed to inhibit HBV entry into cells, reduce the number of virion and subvirion particles in the blood, and potentially function as a therapeutic T cell vaccine. A third poster presentation will focus on the impact of chronic HBV and its treatments on patients’ lives, as well as the perceived value of a functional cure.
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.